A combination of three chemotherapy drugs called mFOLFOX6 is a standard treatment for metastatic colorectal cancer. Bevacizumab is also used to treat this disease; it works by inhibiting the development of the blood vessels that tumors need to grow and spread, by blocking the activity of a protein called VEGF.
Tivozanib is an investigational drug that also blocks tumor blood vessel development by targeting VEGF. In this study, researchers are comparing the safety and effectiveness of tivozanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer. Patients will be randomly assigned to receive one dug combination or the other, but not both.
Tivozanib is a pill that is taken orally (by mouth). The other medications are given intravenously (by vein).